loading
Keros Therapeutics Inc stock is traded at $11.15, with a volume of 415.45K. It is up +0.46% in the last 24 hours and up +0.00% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$11.08
Open:
$11.34
24h Volume:
415.45K
Relative Volume:
0.27
Market Cap:
$452.06M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.1735
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
+3.16%
1M Performance:
+0.00%
6M Performance:
-76.71%
1Y Performance:
-83.83%
1-Day Range:
Value
$11.03
$11.37
1-Week Range:
Value
$10.63
$11.43
52-Week Range:
Value
$9.775
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Name
Keros Therapeutics Inc
Name
Phone
617-314-6297
Name
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Employee
169
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
KROS's Discussions on Twitter

Compare KROS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KROS
Keros Therapeutics Inc
11.14 452.06M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.10 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.63 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
633.30 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.11 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.75 27.34B 3.30B -501.07M 1.03B -2.1146

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-21-25 Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-17-25 Downgrade Wedbush Outperform → Neutral
Dec-16-24 Downgrade Guggenheim Buy → Neutral
Dec-16-24 Reiterated Oppenheimer Outperform
Dec-13-24 Reiterated H.C. Wainwright Buy
Dec-12-24 Downgrade BTIG Research Buy → Neutral
Dec-12-24 Downgrade TD Cowen Buy → Hold
Dec-12-24 Downgrade William Blair Outperform → Mkt Perform
Nov-05-24 Initiated Jefferies Buy
Oct-24-24 Initiated Cantor Fitzgerald Overweight
Oct-16-24 Initiated Scotiabank Sector Outperform
Sep-23-24 Initiated Guggenheim Buy
Jun-25-24 Initiated Oppenheimer Outperform
Feb-21-24 Initiated William Blair Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Jul-31-23 Initiated Wedbush Outperform
Jul-26-23 Initiated BofA Securities Buy
Feb-14-23 Initiated Cowen Outperform
Oct-18-22 Initiated Truist Buy
Jul-26-22 Initiated BTIG Research Buy
Dec-08-20 Reiterated H.C. Wainwright Buy
May-04-20 Initiated H.C. Wainwright Buy
May-04-20 Initiated Jefferies Buy
May-04-20 Initiated Piper Sandler Overweight
May-04-20 Initiated SVB Leerink Outperform
View All

Keros Therapeutics Inc Stock (KROS) Latest News

pulisher
05:58 AM

(KROS) On The My Stocks Page - Stock Traders Daily

05:58 AM
pulisher
05:11 AM

Q1 EPS Forecast for Keros Therapeutics Lifted by Analyst - Defense World

05:11 AM
pulisher
04:50 AM

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

04:50 AM
pulisher
03:47 AM

FY2026 EPS Estimate for Keros Therapeutics Lifted by Analyst - MarketBeat

03:47 AM
pulisher
03:15 AM

What is William Blair’s Forecast for KROS Q1 Earnings? - Defense World

03:15 AM
pulisher
Mar 02, 2025

Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat

Mar 02, 2025
pulisher
Mar 02, 2025

Y Intercept Hong Kong Ltd Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Mar 02, 2025
pulisher
Mar 02, 2025

Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00 - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Q2 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Keros Therapeutics CEO to Speak at Major Conferences - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

When and Where to Hear Keros Therapeutics' Latest Updates: CEO's March Conference Schedule - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Wells Fargo & Company Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $40.00 - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Keros Therapeutics stock target cut to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

Analyst Expectations For Keros Therapeutics's Future - Benzinga

Feb 27, 2025
pulisher
Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Keros Therapeutics Strengthens Financial Position Amid R&D Expansion - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Keros Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

How Keros Therapeutics Secured Funding Until 2029 Despite Widening Losses - StockTitan

Feb 26, 2025
pulisher
Feb 22, 2025

Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday - MarketBeat

Feb 22, 2025
pulisher
Feb 20, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Growth in Short Interest - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - Defense World

Feb 18, 2025
pulisher
Feb 16, 2025

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN

Feb 16, 2025
pulisher
Feb 14, 2025

Institutional owners may consider drastic measures as Keros Therapeutics, Inc.'s (NASDAQ:KROS) recent US$55m drop adds to long-term losses - Simply Wall St

Feb 14, 2025
pulisher
Feb 13, 2025

Research Analysts Issue Forecasts for KROS FY2028 Earnings - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

There is no way Keros Therapeutics Inc (KROS) can keep these numbers up - SETE News

Feb 13, 2025
pulisher
Feb 11, 2025

Examining the Potential Price Growth of Keros Therapeutics Inc (KROS) - Knox Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Has Positive Outlook of KROS FY2028 Earnings - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

(KROS) Proactive Strategies - Stock Traders Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Feb 10, 2025
pulisher
Feb 07, 2025

KROS Shares Experience Surge in Value - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

24,493 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by SG Americas Securities LLC - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Examining Keros Therapeutics Inc (KROS) stock is warranted - US Post News

Feb 06, 2025
pulisher
Feb 06, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Feb 06, 2025
pulisher
Feb 04, 2025

Cantor Fitzgerald Downgrades Keros Therapeutics Inc (KROS) to a Neutral from an Overweight - Knox Daily

Feb 04, 2025
pulisher
Feb 04, 2025

An analyst sees good growth prospects for Keros Therapeutics Inc (KROS) - SETE News

Feb 04, 2025
pulisher
Feb 04, 2025

SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Feb 04, 2025
pulisher
Feb 02, 2025

Exchange Traded Concepts LLC Makes New $99,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Feb 02, 2025
pulisher
Jan 31, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Jan 31, 2025
pulisher
Jan 30, 2025

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider

Jan 30, 2025
pulisher
Jan 30, 2025

Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks

Jan 30, 2025
pulisher
Jan 30, 2025

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times

Jan 30, 2025
pulisher
Jan 30, 2025

Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan

Jan 30, 2025

Keros Therapeutics Inc Stock (KROS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Keros Therapeutics Inc Stock (KROS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
ORBIMED ADVISORS LLC
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
$78.28
price down icon 4.34%
$23.06
price up icon 1.68%
$33.94
price up icon 1.01%
$19.96
price down icon 4.11%
biotechnology ONC
$245.22
price down icon 9.75%
$112.79
price down icon 0.24%
Cap:     |  Volume (24h):